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Abstract There is some controversy amongst respiratory physicians over the value of domiciliary nebuliser use for
chronic lung conditions. Most recommendations for assessment of suitability for this form of treatment rely upon re-
sponse to lung function tests and reported improvements in exercise ability.Relatively little emphasis has been placed
uponthe patient viewof this therapy.This surveyexamined the subjective views of patients receiving domiciliarynebuli-
sersregarding this treatment.Apostalquestionnairewas sentto 82 patientsusinghomenebuliser treatmentprovidedby
therespiratoryclinic atWhippsCrossUniversityHospital,London.Itconsistedof 29 structuredquestionscovering topics
of well-being and symptom control, self-confidence, dependency, time and technical issues, as well as side effects and
compliance. Most patients surveyed had chronic obstructive lung disease. For almost all sections of the questionnaire
patients reported overwhelmingly that the benefits of using a nebuliser outweighed potential disadvantages.The main
perceived advantageswerethe ability forpatients themselves to control symptoms andtobeless dependentonGeneral
Practitioners, hospitals and carers.Compliance was generally excellent, and the reported side effects were minor and
relatively infrequent.Theresults strongly supporttheview thatnebulisers arehelpfulinmanagingchronic lungdisease in
the community, with benefitto patientwell-beingandpotentialhealth cost savings.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1292, available online at http://www.idealibrary.comon
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The prescription of domiciliary nebuliser treatment for
chronic obstructive pulmonary disease (COPD) is a con-
troversialmedical intervention. It is a relativelyexpensive
treatment (1,2) and it requires a designated support ser-
vice to ensure appropriate usage and tomaintain and re-
place the equipment (3^6).The objective clinical e⁄cacy
of nebulisedbronchodilators in COPDremains question-
able. Previous studies have shown a lack of improvement
of lung function tests for many patients (7^9) and have
failed to provide evidence that domiciliary nebuliser
treatment reduces admissions to hospitals or shortens
hospital length of stay (10).Received and accepted in revised form 2 January 2002.
Correspondence should be addressed to: C.Michael Roberts,MD,
FRCP,Consultant Respiratory Physician,Chest Clinic,Whipps Cross
UniversityHospital,Whipps Cross Road,Leytonstone,London E111NR,
U.K.Fax: (0044)-208 535 6709; E-mail:
michael.roberts@whippsx.nhs.ukDespite this evidence nebulisers arewidely prescribed
for the long-term treatment of COPD in the community.
One important reason for the continuing high level of
use in the community is the subjective bene¢t many pa-
tients appear to experience while using nebulisers at
home. Some studies have con¢rmed an increased quality
of life for users of domiciliary nebulisers, with many pa-
tients reporting that they feel less breathless (10^13). In
contrast regular use of high-dose bronchodilating agents
produce side e¡ects such as intolerable tremor, tachy-
cardia and even cardiac arrhythmias that may o¡set the
quality of life improvements from bronchodilation (14).
It is the patient that often demands a nebuliser and
then asks to continue with the therapy; yet, to our
knowledge, no study has speci¢cally explored the rea-
sons for this andpatients’own attitudes to the long-term
use of nebulisers for the treatment of COPD.This study
attempts to address this issue with particular reference
to the perceivedbene¢ts and disadvantages of long-term
nebuliser use in such patients.
376 RESPIRATORYMEDICINEPATIENTSANDMETHODS
A detailed postal questionnaire was sent to all 82 pa-
tients, who were receiving home nebuliser treatment
provided by the respiratory clinic at Whipps Cross
University Hospital, London, U.K. Patients who failed
to return the questionnaire were then reminded to
complete the form by a phone call from the nurse
specialist.
All the patients had previously undergone a detailed
assessment for their suitability for treatment as sug-
gested by the British Thoracic Society guidelines pub-
lished in1997 (15). A dedicated service led by a specialist
respiratorynursebased at theChest Clinic supports the
patients andmonitors servicing andmaintenance of their
technical equipment.
The ¢rst part of the questionnaire consisted of 24
questions following a scaling system suggestedbyHyland
et al. (16).This system assigns the following scores to the
individual responses: ‘strongly agree’ (5), ‘agree’ (4), ‘not
sure’ (3),‘disagree’ (2) and ‘strongly disagree’ (1).The ques-
tionnaire was composed of questions included on the
grounds ofmedical importance and fromideas generated
by a local patient support group (Waltham Forest
Breathe Easy) as relevant to their quality of life as suf-
ferers from chronic lung disease. Questions were
grouped into the following categories: (A) well-being
and symptom control, (B) self-con¢dence, (C) depen-
dency, (D) time issues, (E) technical issues, and (F) Gen-
eral impressions.Thirteen of the questions related to the
possible advantages to be gained by use of home nebuli-
sers; the other11questions concerned thepossible disad-
vantages of the treatment.
Generally, a response was counted as positive, when
the questionwas answeredwith‘strongly agree’or‘agree’.
It was counted as negative, if the answer was ‘disagree’
(2) or ‘strongly disagree’ as suggested by Hyland et al.
(16) for easier data interpretation. For statistical analysis
aChi-square testwasused (on Excelr,Microsoft,U.S.A.)
A null-hypothesis was arti¢cially constructed by as-
suming an equal number of answers accounting for a po-
sitive (‘strongly agree’ and ‘agree’, see above under
Patients andMethods) and a negative response (‘strongly
disagree’ and ‘disagree’, see above), thus implying that
therewould not be a statistically signi¢cant di¡erence in
the opinion of the group.This value was compared with
the actual answers received.This way a Chi-square value
was calculated.With a con¢dence interval of 95% all Chi-
valueswith a Po0.05 are signi¢cant (Po0.01highly signif-
icant). A second part of the questionnaire consisting of
four questions was designed to examine the compliance.
Patients were asked the recommended frequency of
usage when started with their treatment, how often
they use it currently, and if there was a change made,
who was responsible, and ¢nally what the reasons for a
changewerewhen onewasmade.With the last set of questions we wanted to ¢nd out
about the possible side e¡ects and the frequency of their
occurrence (often, seldom, never).
RESULTS
Seventy ¢ve out of 82 patients returned the question-
naire providing a 91.5% response rate. The median
age was 71.5 years (71.578.6); 45.3% were female,
54.7% male. The median FEV1 was 40% (40715%) of
predicted.
The drugs used for the nebuliser treatment were
either salbutamol and/or ipratropium bromide. Thirty-
two per cent used only a single drug, 56% both. Twelve
per cent used additionally an inhaled glucocorticoid or
normal saline.
Outof those 75 patients returning their questionnaire
57 (76%) had COPD, 6 (8%) su¡ered from asthma, 2 (3%)
frombronchiectasis,1 (1%) each accounted for allergic al-
veolitis and thoracoplasty post-surgery for tuberculosis.
The diagnosis of 8 (11%) patients was unspeci¢ed (‘short-
ness of breath’).
Overall, patients reported overwhelmingly that the
bene¢ts of using a nebuliser at home far outweighed the
disadvantages (98.2% vs.1.8%).
The majority strongly agreed or agreed that using
domiciliary nebulisers made a big di¡erence to their life.
The summarised results of the questionnaire are re-
ported inTables1and 2.
ADVANTAGESOFNEBULISERUSE
The main advantages that were reported by a majority
of patients can be categorised as (a) an increased
feeling of personal well-being, (b) better symptom con-
trol, (c) an increased con¢dence and (d) the perception
of greater independence. (For detailed results see also
table1).
In category A the majority of the questioned patients
felt that the nebulisers help them e¡ectively to reduce
the symptoms of their chronic respiratory disease.
Most patients agreed that their chest felt more comfor-
table after using the nebuliser.
Nearly, three quarters of the patients found the
nebulisers superior to their inhalers in symptom
relief.Breathing was commonly reported asmuch easier
after using a nebuliser.More than half of the participants
felt they could walk further following nebuliser
treatment.
Most users of home nebulisers also felt more in con-
trol of their disease as re£ected in the results of the ca-
tegory B questions:
Three-quarters agreed with the statement that
the nebuliser treatment would keep them out of
hospital. The majority also thought, their need for
TABLE 1. Advantages of nebuliser treatment
Strongly
agree
Agree Not
sure
Disagree Strongly
disagree
Positive
answers
(% oftotal
in brackets)
Negative
answers
(% oftotal
in brackets)
Chi-square
Category A: well-being and symptom control
Chestmore comfortable 21 36 4 0 2 57 (76.0) 2(1.8) 49.44
Helps breathingmore than inhalers 22 31 11 3 2 53(70.7) 5(6.67) 39.72
Canwalk further afternebulisers 13 29 16 12 0 42(56.0) 12(16.0) 16.67
Makesbreathingeasier 30 38 4 0 1 68(90.7) 1(1.3) 67.03
Category B: self-con¢dence
Canhelpmyselfmore 20 38 12 1 2 58(77.3) 3(4.0) 51.42
Helps to keepme outof hospital 27 29 15 0 0 56(74.7) 0(0) 56.00
Need less help fromfriends/family 10 37 8 13 2 47(62.7) 15(20.0) 16.52
Call GP less 17 36 9 7 2 53(70.7) 9(12.0) 31.23
More independent since usingnebs 13 33 19 5 1 46(61.3) 6(8.0) 30.77
More in charge of symptomcontrol 21 38 9 1 0 59(78.7) 1(1.3) 56.07
Category F: general impressions
Bigdi¡erence to life 17 40 11 4 0 57(76.0) 4(5.3) 41.82
Lostwithoutnebulisers 36 23 6 5 0 59(78.7) 5(6.7) 45.56
Advantages of usinghomenebulisers categorised.Thepatientswere confrontedwith a statement andhadto decidewhether
to strongly agree, agree, being not sure, disagree or strongly disagree. Strongly agree and agree (5 and 4) were counted as
positive response to a statement, disagree and stronglydisagree (1and 2) as negative response (see also Methods).The number
of completed questionnaireswas 75.Bold numbers show thatthe result is highly signi¢cant (Po0.01). Allresults in this table are
highly signi¢cant!
TABLE 2. Disadvantages of nebuliser treatment
Strongly
agree
Agree Not
sure
Disagree Strongly
disagree
Positive
answers
(% oftotal
in brackets)
Negative
answers
(% oftotal
in brackets)
Chi-square
Category C:Dependency
Worry to becometoo dependent 16 19 12 20 4 35(46.7) 24(32.0) 1.7
Worryin case nebuliser brakes down 15 19 6 27 3 34(45.3) 30(40.0) 0.25
Feel totallydependent 9 15 23 18 2 24(32.0) 20(26.7) 0.36
Category D: time issues
Takesup a lotoftime during the day 3 22 5 29 14 25(33.3) 43(57.3) 4.76
Good e¡ects do not last longenough 10 15 14 17 2 25(33.3) 19(25.3) 0.82
Dayresolves around treatment 7 18 5 34 9 25(33.3) 43(57.3) 4.76
Category E:Technical issues
Too heavy to carry 14 21 3 25 6 35(46.7) 31(41.3) 0.24
Restricts fromgoing outduring the day 8 8 2 42 8 16(21.3) 50(66.7) 17.52
Restricts fromgoing onholidays 8 7 7 33 11 15(20.0) 44(58.7) 14.37
Embarrassed to use inpublic 9 16 5 27 11 25(33.3) 38(50.7) 2.29
Di⁄cultto keep clean 3 8 1 39 15 11(14.7) 54(72.0) 27.14
Disadvantages of using home nebulisers categorised. The patients were confronted with a statement and had to decide
whether to strongly agree, agree, being not sure, disagree or strongly disagree. Strongly agree and agree (5 and 4) were
counted as positive response to a statement, disagree and strongly disagree (1and 2) as negative response (see also Methods).
Thenumberof completed questionnaireswas 75.Boldnumbers ofthe chi-square value show, thattheresult is highly signi¢cant
(Po0.01).Italic numbers ofthe chi-square value indicate, thattheresultwas signi¢cantwith a Po0.05.Normalprintednumbers
ofthe chi-square valuemean a non-signi¢cant result.
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378 RESPIRATORYMEDICINEhelp by their family was less, and additionally they
needed to call theirGP less often for help thanbefore.
Patients felt much more in charge of their symptom
control and that they could help themselves more
once they used a nebuliser. This brought with it a
general impression of greater independence.
DISADVANTAGES (RESULTS SEE
ALSOTABLE 2)
Most respondents felt they would be lost without their
nebulisers.This feeling promotes increasing dependence
on their treatment (category C).
One-third felt totally dependant on their nebulisers.
Nearly, half of the surveyed patients were worried that
they would become too dependent on their nebulisers.
Although the time taken to nebulisemedication is an-
other potential drawback to this form of treatment few
patients had the impression that their day revolved
around the treatment.
Only one-third felt that the treatment took up a lot of
time.
Problemswithmaintenance of the equipmentor tech-
nical di⁄culties (category E) were identi¢ed as another,
but only a minor disadvantage of home nebuliser treat-
ment.
Mostpeople didnotexperience anyproblemswithkeep-
ing their equipment clean.
Half of the group thought the nebuliser machine to be
too heavy to be carried around.
This could be a possible reason, why one-¢fth of the pa-
tients feltrestricted fromgoingonholidays, although the
majority was quite happy to go on holidays once in a
while.
Few people felt restricted in going out during the day by
the treatment. Some felt embarrassed when using their
nebuliser in public.TABLES 3. Compliance issues
(a) Data on how often the patients were advised by the chest C
oftenpatients used their nebuliser in reality (n=totalnumberof a
Howoftento use perday? 1
Advise by specialistof daily usage 2 (2.7%) 20
Daily usage by the patient 5 (6.7%) 16
(b) Data onhowoften changesweremade intotal (24 times), an
pants inthe questionnaire:75
Changesmade to advised frequency Total On
s
Use itmore often! 15 (50.0%) 9
Use it less often! 15 (50.0%)COMPLIANCE
The next set of questions related to the compliance of
patients with the frequency of use at home (see also
Table 3a and b).
Changes in frequency weremade in 40% of the cases.
Fiftyper centof those changeswere orderedby ahealth-
care worker (either hospital consultant, GP or Respira-
tory nurse), but in 50% users themselves initiated
changes.
Interestingly, when a medical specialist felt a change
was required, it was generally to an increase in use. If
the patients made the change, the frequency was more
often reduced than increased.
Reasons for any change (either increasing or decreas-
ing the frequency) by the patientwere a recent chest in-
fection (10 patients), the impression that the treatment
did not last long enough (4 patients) or did notreally help
(3 patients), the side e¡ects, improvement of the condi-
tion, varying symptoms, fear of becoming too depen-
dent, and that the treatment would absorb too much
time (each of the last reasons had one quotation).
SIDEEFFECTS (SEEALSOFIG.1)
The side e¡ect, experienced most, was a dry mouth.
Forty-eight per cent of the patients had often a dry
mouth after using the nebuliser.
The next commonest side e¡ect was change in taste
followed by tremor and palpitations. A rare side e¡ect
was angina.Only 13.5% experienced angina (5.3% often,
6.7% seldom, 53.3% never).More commonly people com-
plained of chest tightness connected with nebuliser use:
just 9.3% had often a tight chest after using their nebuli-
ser, but 26.7% had this impression now and again (40.0%
never).linic specialist to use their nebulisers at home in 24 h, and how
nswers.Percentage in brackets)
2 3 4 More
(26.7%) 10 (13.3%) 35 (46.7%) 2 (2.7%)
(21.3%) 12 (16.0%) 32 (42.7%) 6 (8.0%)
d if theyweremade, whose decision it was.Numberof partici-
advice of
pecialist
Owndecision
(81.8%) 6 (31.6%)
2 (18.2%) 13 (68.4%)
0%
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20%
30%
40%
50%
60%
70%
80%
90%
100%
Tremor Chest
tightness
Palpitations Angina Dry mouth Changes in
taste
FIG. 1: Side e¡ects as experienced by participants.Three-di-
mensional graph on the commonly experienced side e¡ects of
domiciliary nebuliser use.One hundred per cent is actually not
equivalentto the total number of answers in each category.Only
positive answers were counted for this graph. Not answering
this part of the questionnaire positively was counted as ‘never’
tomakeupto atotalnumberof 75.For the actualexactnumbers
andpercentages refer to the article.
APATIENTS’PERSPECTIVEONHOMENEBULISERS 379Side e¡ects with only one quotation each were giddi-
ness, mouth ulcers, mouth thrush, muscle cramps, slee-
piness, watery eyes and feeling out of breath.
DISCUSSION
Absolute indications for nebuliser treatment are only
very few: drug formulation, e.g. rhDNase (not applicable
in asthma and COPD patients), or patients too sick or
disabled to use handheld inhalers (9). It is very often left
to the clinician’s choice to commence patients on nebuli-
ser treatment.
The British Thoracic Society as well as the ERS has
strict guidelines for the use of domiciliary nebuliser
treatment (15,17). In severe COPD, it recommends an as-
sessment of every candidate by a respiratory physician.
Eligible patients should undergo a short trial at home.
Criteria, which promise bene¢t from home nebuliser
treatment are: (a) an objective treatment responsewith
an increase of more than 15% in the baseline peak £ow
rate or, if this is not the case, (b) the clinician’s judge-
ment, when the patient experiences subjective bene¢ts.
Only a limited number of COPD patients are likely to
qualify for a nebuliser using the ¢rst criterion, which by
de¢nition labels almost all patients as asthmatic.On the
other hand, asMuers discusses in detail (9), ameasurable
increase in peak £ow does not necessarily correspond
with psychological and subjectivebene¢ts. Small changes
in a patientwith severely impairedlung function canhave
a big impact on symptoms (18).This might be the case by
other possible mechanisms besides bronchodilatation
like an increased cardiac output or cerebral blood £ow.Impact on survival andmortality of domiciliary nebuli-
sers vs inhalers could not be shown (13).The second cri-
terion covers these possible mechanisms but none are
easilymeasurableby the clinician andresult in an entirely
subjective decision being taken by the physician in many
cases.
The frequency of side e¡ects reported in our ques-
tionnaire is relatively low and (the most frequent being
tremor and dry mouth) correlates well with other stu-
dies (12).
Serious side e¡ects of especially beta-agonists, like
symptoms of cardiac ischaemia or arrhythmias, were re-
ported, but only in a few patients, although those could
have dramatic consequences (19). Previous published re-
sults show that those side e¡ects are mostly mild to
moderate in nature, and deaths due to cardiac causes
are very rare (12,15). A ¢nding supporting this statement
was that in random blood samples of acute admissions
for exacerbation of asthma the systemic levels of beta-
agonists were not di¡erent in people with or without
domiciliary nebulisers (10).
Generally, side e¡ects relate to the amount of drug
used during the day, at least for beta-agonists (14,20).
The compliance to treatment in our patientgroupwas
good (around 75%). Interestingly changes to recom-
mended dosing tended to decrease in frequency than to
increase, which is reassuring regarding the safety issues.
Bosley et al. (11) showed recently (the adherence
to treatment in their study was 44%) that the adherence
to prescribed home nebuliser treatment highly
depends on the quality of life, the patient experiences,
depression and the feeling of being supported.This again
emphasises the importance of a proper set-up of a
nebuliser service, which should be run by specialist
personnel. It also demonstrates that, if the target to
provide a consistent better symptomrelief and herewith
quality of life is met, the compliance will automatically
increase.
Generally, the results of this study strongly support
the patient perception that nebulisers are helpful in the
management of chronic lung disease, and especially
COPD in the community. In particular, a high percentage
of these patients felt that their nebulisers hadmade a big
di¡erence to their lives and that they wouldbe lostwith-
out them. This result is in general agreement with the
workof Muers (9), but contrastswith themedical estab-
lishment attitude that nebulisers have a limited role in
long-term management of COPD (7,8,10). The reasons
for this apparent anomaly are stated in the introduction.
The cost of the treatment is certainly an issue, but if the
patients’ perception that this treatment keeps them out
of hospital andreduces calls on their GP is true, the cost-
bene¢t changes. Certainly a previous study (10) contra-
dicts this, showing no reduction in admission, and re-
cently a national audit of COPD admissions in the U.K.
identi¢ed multiple drug use and nebuliser treatment on
380 RESPIRATORYMEDICINEdischarge as a predictor of readmission (21). Neverthe-
less, nebuliser use in this contextmay be a marker of se-
verity, and this could confound results of studies
examining di¡erent populations. Itmay be that the mod-
erately severe patient may bene¢t with reduced admis-
sions if given nebuliser treatment at home, whereas the
severely ill COPD patient has gone beyond this aspect of
treatment bene¢t. The study of Godden (22), where
COPD admissions were avoided by providing hospital at
home-type services certainly support this notionwhere
nebuliser use and nursing support were the main inter-
ventions used to keep the less severely ill patient from
admission. This study provides a perception, but is not
conclusive. Further research should be targeted at this
issue, and prospective randomised trials designed to ad-
dress this question.
Symptom control is also reported as better andmost,
but not all patients felt that nebulisers weremore e¡ec-
tive than inhalers in helping their breathing. It is perhaps
more surprising to understand, why patients, who an-
swered negatively to this question continue to use a
nebuliser, but itmaybe that the patients get other bene-
¢ts as noted above that reinforce the use of their treat-
ment.This is an important issue for doctors, who often
dispense nebulisers on the basis of changes in lung func-
tion parameters or in some suggestion of reduced
breathlessness or increased exercise ability. The results
of this questionnaire suggest that the e¡ect of nebuliser
treatment may be much more complex, involving an in-
teraction between physical, psychological and social
gains.
The disadvantages of nebulisers are all toowell recog-
nised by patients in contrast to medical perception. A
signi¢cant proportion of patients were concerned about
the time taken for usage, the problems of over-reliance
and dependence on treatment, and the di⁄culties that
may arise in the case of equipment failure.The e¡ect that
this may have on compliance is also interesting with pa-
tients tending to reduce their use of nebulisers com-
pared with the recommended frequency. In contrast,
patients who have increased frequency of usage from
the original prescription claim to have done so on the ad-
vice of a physician.
This study is limited by the number of respondents to
the questionnaire, and the fact, that not all the patients
su¡ered from COPD.Nevertheless, the response rate is
fair and similar to other surveys. Even if the ¢ne detail is
obscuredpatientviews about their treatment are impor-
tant, and this study raises some interesting issues.
The importance of involving patients and their percep-
tions of quality of life in treatment choices for cancer
has recently been highlighted (23). This study suggests
that a more patient-centred approach to nebuliser
prescription may provide bene¢ts to patients not mea-
surable by traditional lung function testing and physi-
cian-estimated bene¢ts to exercise capacity. Moredetailed enquiry as to the perceived patient bene¢ts of
nebuliser treatment using structured questionnaires
may allow clinicians to make more rationale decisions in
prescribing this treatment following a trial of nebuliser
therapy.
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